Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Esmaeilzadeh Hossein, Askarisarvestani Aida, Hosseini Nazanin, Samimi Sahar, Shafiei Alireza, Mahdaviani Seyed Alireza, Eslami Narges, Chavoshzadeh Zahra, Fallahi Mazdak, Khakbazanfard Nasrin, Shabestari Mahnaz Sadeghi, Aleyasin Soheila, Nabavizadeh Seyed Hesamedin, Cheraghi Taher, Kalantari Arash, Ahmadiafshar Akefeh, Safari Mojgan, Eslamian Mohammad Hossein, Molatefi Rasol, Shirkani Afshin, Heidarzadeh Arani Marzieh, Tavakol Marzieh, Bemanian Mohammad Hassan, Arshi Saba, Nabavi Mohammad, Shokri Sima, Shahhosseini Babak, Mortazavi Negar, Nakhaei Pooria, Nazari Farzad, Fallahpour Morteza, Ahanchian Hamid, Moazzen Nasrin, Khoshkhui Maryam, Motlagh Ahmad Vosughi, Aghamohammadi Asghar, Abolhassani Hassan, Yazdani Reza, Rezaei Nima
Аннотация
METHODS: Data of IVIg infusions in IEI patients were collected from 2011 to 2021. Totally, 363 IEI patients received IVIg regularly in Iran entered the study. The adverse reactions are classified regarding their severity and chronicity.
RESULTS: 22,667 IVIg infusions were performed in the study. 157 patients (43.2%) and 1349 (5.9%) infusions were associated with at least one type of adverse reaction. The highest rates of adverse reactions were seen in severe combined immunodeficiency. Myalgia, chills, headache, fever, and hypotension were the most frequent adverse effects of IVIg.
CONCLUSION: The reactions affect almost half of the patients mainly in the first infusions which necessitate the close observation of IEI patients receiving IVIg.